Table 1 Baseline characteristics of patients and tumours grouped by HPV results
All 138 patients | Group 1 (n = 59) ‘True’ negatives p16 negative PCR & ISH negative | Group 2 (n = 6) 'Equivocal' p16 negative PCR &/or ISH positive | Group 3 (n = 69) ‘True’ positives p16 positive PCR &/or ISH positive | Group 4 (n = 4) 'Equivocal' p16 positive PCR & ISH negative | Test comparing groups 1 & 3 | |
|---|---|---|---|---|---|---|
Male | 104 (75%) | 44 (75%) | 5 | 51 (74%) | 4 | X2 1: p = 0.93 |
Female | 34 (25%) | 15 (25%) | 1 | 18 (26%) | 0 | |
Age in years Mean (SD) | 58.1 (10.7) | 61.6 (10.1) | 57 (7.9) | 55.7 (10.9) | 48.8 (0.5) | t: p = 0.002 |
Smoking* | ||||||
Current | 63 (55%) | 41 (80%) | 4 | 18 (32%) | 0 | X2 2: p < 0.001 |
Previous | 32 (28%) | 9 (18%) | 0 | 23 (41%) | 0 | |
Never | 20 (17%) | 1 (2%) | 2 | 15 (27%) | 2 | |
Performance status | ||||||
0 | 68 (49%) | 15 (25%) | 4 | 46 (67%) | 3 | MW: p < 0.001 |
1 | 42 (30%) | 21 (36%) | 1 | 19 (28%) | 1 | |
2 | 21 (15%) | 17 (29%) | 0 | 4 (6%) | 0 | |
3 | 7 (5%) | 6 (10%) | 1 | 0 (0%) | 0 | |
Primary tumour site | ||||||
Tonsil | 93 (67%) | 33 (56%) | 4 | 54 (78%) | 2 | X2 2: p < 0.001 |
Tongue base or vallecula | 35 (25%) | 16 (27%) | 2 | 15 (22%) | 2 | |
Other1 | 10 (7%) | 10 (17%) | 0 | 0 (0%) | 0 | |
AJCC stage | ||||||
I | 5 (4%) | 5 (8%) | 0 | 0 (0%) | 0 | MW: p = 0.53 |
II | 5 (4%) | 3 (5%) | 0 | 2 (3%) | 0 | |
III | 28 (20%) | 8 (14%) | 0 | 20 (29%) | 0 | |
IVA | 87 (63%) | 35 (59%) | 5 | 43 (62%) | 4 | |
IVB | 8 (6%) | 3 (5%) | 1 | 4 (6%) | 0 | |
IVC | 5 (4%) | 5 (8%) | 0 | 0 (0%) | 0 | |
Primary treatment | ||||||
Surgery | 71(51%) | 21 (36%) | 4 | 42 (61%) | 4 | X2 1: p = 0.07 |
Radiotherapy | 55 (40%) | 27 (46%) | 1 | 27 (39%) | 0 | |
Radical | 126 (91%) | 48 (81%) | 5 | 69 (100%) | 4 | X2 1: p = 0.001 |
Palliative | 12 (9%) | 11 (19%) | 1 | 0 (0%) | 0 | |
DNA Adequacy | ||||||
HMBS positive | 83 | 32 (39%) | 4 (5%) | 46 (55.4%) | 1 (1%) | |
HMBS negative | 55 | 27 (49%) | 2 (4%) | 23 (42%) | 3 (5%) | |
All cases | 138 | 59 (43%) | 6 (4%) | 69 (50%) | 4 (3%) | |